SGLT2 inhibitors showed robust respiratory protection that appeared largely independent of diabetes status, GLP-1 receptor agonists may provide benefit in obesity, and DPP-4 inhibitors offered limited advantage with a potential asthma risk. This evidence concerns the gene DPP4 and obesity due to melanocortin 4 receptor deficiency.